Sai Life Sciences Limited, one of India’s fastest-growing Contract Research, Development and Manufacturing Organizations (CRDMO), has reported robust financial results for Q3 and nine months ended December 2025, driven by strong growth in both CRO and CDMO services.

Q3FY26 revenue rose to Rs. 556 crore, up 27% from Rs. 440 crore in Q3FY25; EBITDA was Rs. 191 crore, up 54%; margin expanded to 34% from 28%; and PAT surged to Rs. 100 crore, up 86% from Rs. 54 crore.

For the nine-month period, Sai Life Sciences recorded Rs. 1,590 crore in revenue (+43%), EBITDA of Rs. 472 crore (+79%), and PAT of Rs. 245 crore (+199%), reflecting strong operational execution and sustained demand.

The company accelerated adoption of AI and digital platforms, delivering AI-designed macrocyclic peptides and applying AI-driven retrosynthetic analysis to enhance synthetic efficiency. It also strengthened its photochemistry, electrochemistry, and flow chemistry capabilities, while implementing high-throughput and automated experimentation in discovery and process development.

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26, signaling continued investment in scalable infrastructure. Sai Life Sciences also emphasized quality and sustainability, completing eight customer audits with zero critical observations and securing My Green Lab Green-level certification for four laboratories.

CEO Krishna Kanumuri commented, “Q3 FY26 marked continued progress in building Sai Life Sciences into a science-led, globally relevant CRDMO. During the quarter, we strengthened our technology platforms through greater adoption of digital, AI-enabled and modern chemistry approaches, enhancing our ability to support increasingly complex programs for global innovator clients.

"In parallel, we continued to build organizational depth by adding experienced scientific and leadership talent, ensuring our teams scale in step with our expanding capabilities. Our capacity expansion plans remain firmly on track, with manufacturing scale-up and process development infrastructure progressing in line with our long-term roadmap. These investments are being guided by the evolving scientific contours of next-generation medicines and the changing needs of our customers.

"Looking ahead, we remain confident in sustaining our growth momentum in the coming year. With disciplined execution and a clear strategic direction, Sai Life Sciences is well positioned to support the next phase of innovation while creating long-term value for all stakeholders."

CFO Siva Chittor added, “We have delivered a robust growth in Q3 FY26 which outperformed the broader CRDMO industry trend, with improved operating performance, driven by disciplined execution and healthy momentum across our businesses.

"For the quarter, total revenue stood at Rs. 556 Cr, representing a 27% year-on-year increase, supported by sustained demand and healthy volume growth across key service lines. EBITDA grew by 54% year-on-year to Rs. 191 Cr, with margins expanding by 605 bps to 34%, supported by improved capacity utilization, operational efficiencies, and ongoing cost optimization initiatives."

He added: "As of date, we have invested Rs. 405 Cr in capital expenditure, aligned with our long-term strategy to strengthen capabilities and expand capacity. This investment remains in line with our guided FY26 capex plan and reinforces our commitment to building scalable, future-ready infrastructure.

"We continue to focus on prudent capital allocation and margin discipline while investing selectively in areas that enhance our differentiated value proposition. With strengthened capabilities, a solid order pipeline, and a more resilient operating foundation, we are well positioned for another year of strong and profitable growth, creating enduring value for our stakeholders.”